首页|纳米药物治疗原发性肝癌的研究进展

纳米药物治疗原发性肝癌的研究进展

扫码查看
目前手术结合化疗药物仍是原发性肝癌(primary hepatic carcinoma,PHC)的主要治疗手段,但多数化疗药物会造成较严重的不良反应,患者长期获益仍不理想.纳米科技作为新兴学科,可合成纳米级载药微粒,且合成的纳米药物因其具有稳定的理化性质、良好的生物相溶性及较低的毒性等优势在PHC的治疗中应用较多,可通过热疗、靶向化疗、放射治疗等方式发挥多种全新功能,提高治疗效果,改善患者预后.但纳米药物的完整性及稳定性受载体材料影响较大,可能会在一定程度上影响治疗效果,今后还需进一步完善纳米载药技术,以便使纳米药物在PHC的治疗中发挥更好的效果.
Research progress of nano-drugs in the treatment of primary liver cancer
At present,surgery combined with chemotherapy is still the main treatment for primary hepatocellular carcinoma(primary hepatic carcinoma,PHC),but most chemotherapy drugs will cause serious side effects,and the long-term benefits of patients are still not ideal.As a new discipline,nanotechnology can synthesize nano-drugs loaded particles,and the synthetic nano drugs are widely used in the treatment of PHC because of their advantages,such as stable physical and chemical properties,good biocompatibility and low toxicity.It can play a variety of new functions through hyperthermia,targeted chemotherapy,radiotherapy and other treatment methods to improve the treatment effect and prognosis of patients.However,the integrity and stability of nano drugs are greatly affected by the carrier materials,which may affect the therapeutic effect to some extent.In the future,nano drug loading technology needs to be further improved,so that nano drugs can play a better role in the treatment of PHC.

primary liver cancernano-drughyperthermiatargeted chemotherapyradiotherapy

李杏英、杨勤、胡雪原、邓礼林

展开 >

重庆三峡医药高等专科学校 中医学院,重庆 404120

原发性肝癌 纳米药物 热疗 靶向化疗 放射治疗

重庆市教委科学技术研究项目重庆市科委基金重庆三峡医药高等专科学校研究项目第三批重庆市中医药专家学术经验继承项目

KJQN201902705cstc2019jcyjmsxmX07702018xzyb02委办2019-193

2024

沈阳药科大学学报
沈阳药科大学

沈阳药科大学学报

CSTPCD
影响因子:0.604
ISSN:1006-2858
年,卷(期):2024.41(9)